Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip J Stephens

Showing results (31-40 of 168) with videos related to

Pageof 17
Sort By:
Journal of Hematology & Oncology|March 2, 2017
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case reportHong Li, Weijie Ma, Ken Y Yoneda, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Clinical Lung Cancer|January 17, 2017
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 FusionJustin M Allen, Alexa B Schrock, Rachel L Erlich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2008
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencingPeter J Campbell, Erin D Pleasance, Philip J Stephens, et al.
Cancer Discovery|May 31, 2014
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsChristine M Lovly, Abha Gupta, Doron Lipson, et al.
JAMA Oncology|June 16, 2017
Genomic Profiling of Small-Bowel AdenocarcinomaAlexa B Schrock, Craig E Devoe, Robert McWilliams, et al.
Journal of Clinical Pathology|October 27, 2015
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targetsHwajeong Lee, Kai Wang, Adrienne Johnson, et al.
Journal of Medicinal Chemistry|October 17, 2009
Stereoselective behavior of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a new L-type calcium channel blockerEmanuele Carosati, Roberta Budriesi, Pierfranco Ioan, et al.
Pageof 17

Showing results (31-40 of 168) with videos related to

Sort By:
Pageof 17
Journal of Hematology & Oncology|March 2, 2017
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case reportHong Li, Weijie Ma, Ken Y Yoneda, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinibSai-Hong Ignatius Ou, Jean Cui, Alexa B Schrock, et al.
Clinical Lung Cancer|January 17, 2017
Genomic Profiling of Circulating Tumor DNA in Relapsed EGFR-mutated Lung Adenocarcinoma Reveals an Acquired FGFR3-TACC3 FusionJustin M Allen, Alexa B Schrock, Rachel L Erlich, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to AlectinibSai-Hong Ignatius Ou, Samuel J Klempner, Joel R Greenbowe, et al.
Oncotarget|June 15, 2013
Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analysesJennifer Wheler, David Hong, Stephen G Swisher, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 30, 2008
Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencingPeter J Campbell, Erin D Pleasance, Philip J Stephens, et al.
Cancer Discovery|May 31, 2014
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsChristine M Lovly, Abha Gupta, Doron Lipson, et al.
JAMA Oncology|June 16, 2017
Genomic Profiling of Small-Bowel AdenocarcinomaAlexa B Schrock, Craig E Devoe, Robert McWilliams, et al.
Journal of Clinical Pathology|October 27, 2015
Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targetsHwajeong Lee, Kai Wang, Adrienne Johnson, et al.
Journal of Medicinal Chemistry|October 17, 2009
Stereoselective behavior of the functional diltiazem analogue 1-[(4-chlorophenyl)sulfonyl]-2-(2-thienyl)pyrrolidine, a new L-type calcium channel blockerEmanuele Carosati, Roberta Budriesi, Pierfranco Ioan, et al.
Pageof 17